At a glance
ClinicalIndex Comparison Record- ✓First diagnosis of treatment-naïve classical Hodgkin lymphoma
- ✓Early-stage unfavorable disease with specific risk factors (large mediastinal mass, extranodal lesion(s), elevated ESR, or ≥3 nodal areas)
- ✕Nodular-lymphocyte predominant Hodgkin lymphoma
- ✕Grey-zone lymphoma
- ✕Central nervous system involvement of lymphoma
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT04837859Phase 2RecruitingMonitorUpdated 23mo ago · Completion was 2mo agoPhase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Tislelizumab for Classical Hodgkin Lymphoma. Currently recruiting, targeting 120 participants across 1 site.
Signals
Detailed Summary
The aim of the trial is to establish an individualized first-line treatment incorporating checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.
Study Details
Timeline
Interventions
age 18-60: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT if PET positive resudues after the end of Tis or Tis-AVD age 60+: Tislelizumab alone or in combination with AVD (depending on the PET result after 2x Tislelizumab) followed by IS-RT for all patients